http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

erlotinib tablets are a kinase inhibitor indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen 1 1 first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with gemcitabine 1 2 limitations of use safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations 1 1 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy 1 1 erlotinib tablets are indicated for the treatment of patients with metastatic non small cell lung cancer nsclc whose tumors have epidermal growth factor receptor egfr exon 19 deletions or exon 21 l858r substitution mutations as detected by an fda approved test receiving first line maintenance or second or greater line treatment after progression following at least one prior chemotherapy regimen see clinical studies 14 1 14 3 safety and efficacy of erlotinib tablets have not been established in patients with nsclc whose tumors have other egfr mutations see clinical studies 14 1 14 2 erlotinib tablets are not recommended for use in combination with platinum based chemotherapy see clinical studies 14 4 erlotinib tablets in combination with gemcitabine is indicated for the first line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer see clinical studies 14 5

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_3908 DOID_3908

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00530 drugbank:DB00530

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-15T16:17:22.636Z

http://purl.org/np/RA9tplnxsJ... RA9tplnxsJ

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-15T16:17:22.636Z